Based on this data, a growing number of clinical trials proposed to evaluate the clinical efficacy of: check-point inhibitors of soluble mediators (IDO, A2aR, CSF1R, IL-10 or TGFβ), agonistic antibodies targeting and activating receptors on T cells, anti-tumour vaccines 122, 123 and adoptive transfer of CAR T cells 124, 125. Here, IDO1 is linked to neoplasm.